News & Insights

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Functional, Sensorimotor, and Cognitive Outcomes Following Unilateral MCAO in Rats

Behavioral and pharmacological characterization of the isosorbide dinitrate model of headache in male and female rats

Filters

Filters

Therapeutic Areas

Specific Disorders

Filters

A systematic assessment of robustness in CNS safety pharmacology

PsychoGenics Awarded an NIH Contract to Test and Identify Novel Therapeutics for Pain

Sleep/Wake and Pharmaco-EEG Capabilities

Standardized Locomotor and Sensory behavior changes in a graded contusive spinal cord injury model

Characterization of Rat Kindling Models

PsychoGenics Inc. Awarded $3 million SBIR Grant to Employ its AI-enabled Platforms to Find Treatments for Rare Disorders

Characterization of The APP/PS1 Mouse Model of Alzheimer’s Disease

Characterization of The rTg4510 Mouse Model of Alzheimer’s Disease

Comparison of Three Novel Neuroprotective Therapies for Traumatic Brain Injury Using a CCIModel in Rats

Let’s Find the Right Solution Together

Quick Links

Contact

Address

Email

Phone

Fax